Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On February 14, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the first quarter of fiscal year 2025 that ended December 31, 2024 and provided a business update.</li><li>The company recently announced it raised $15 million in a private placement with healthcare-focused institutional investors.</li><li>The funds will be utilized to advance its anti-CXCL10 monoclonal antibody, EB06, for the treatment of vitiligo.</li></ul>

On February 14, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the first quarter of fiscal year 2025 that ended December 31, 2024 and provided a business update.The company recently announced it raised $15 million in a private placement with healthcare-focused institutional investors.The funds will be utilized to advance its anti-CXCL10 monoclonal antibody, EB06, for the treatment of vitiligo.

Edesa Biotech

EDSA: Raises 15 Million to Advance EB06